Wednesday, April 17, 2013

Austin-Based Xeris Pharmaceuticals Receives Phase II NIH Fast-Track Funding to Advance Glucagon for the Artificial Pancreas

Read about how Austin-Based Xeris Pharmaceuticals Receives Phase II NIH Fast-Track Funding to Advance Glucagon for the Artificial Pancreas.

http://bionews-tx.com/news/2013/04/17/austin-based-xeris-pharmaceuticals-receives-phase-ii-nih-fast-track-funding-to-advance-glucagon-for-the-artificial-pancreas/
at
Labels: , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)